Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATARAX vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Pruritus due to allergic conditions (FDA approved),Anxiety and tension (FDA approved for psychoneurosis),Sedation before and after general anesthesia (FDA approved),Off-label: Nausea and vomiting, motion sickness, insomnia
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Primarily hepatic via CYP3A4 and CYP2D6; major metabolite is cetirizine.
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Approximately 93% bound primarily to albumin and alpha-1-acid glycoprotein.
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Approximately 10-15 L/kg; large Vd indicates extensive tissue distribution, including penetration into the central nervous system.
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral bioavailability is approximately 100% (nearly complete absorption) with peak plasma concentrations at 2 hours; intramuscular bioavailability is similar to oral but with faster absorption.
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
GFR 10-50 m L/min: administer every 24 hours. GFR <10 m L/min: contraindicated or reduce dose to 50% every 24 hours.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: contraindicated.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Children >6 years: 0.6 mg/kg orally every 6 hours; maximum 2 mg/kg/day. Children <6 years: 0.5 mg/kg orally every 4-6 hours; maximum 50 mg/day.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Initiate at 12.5 mg orally twice daily; may increase gradually. Avoid use in patients with significant renal impairment or dementia due to anticholinergic effects.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
Not applicable; no black box warning.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
Drowsiness and impairment of alertness; avoid driving or operating machinery,Potentiation of CNS depressants (alcohol, barbiturates, opioids),Anticholinergic effects (urinary retention, blurred vision, constipation),QT prolongation risk (especially with electrolyte disturbances, pre-existing QT prolongation, or concurrent QT-prolonging drugs),Use with caution in elderly due to increased risk of sedation and falls,Tardive dyskinesia with prolonged high-dose use
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Hypersensitivity to hydroxyzine or any component of the formulation,Early pregnancy (first trimester) due to potential fetal harm,Porphyria,Lactation (excreted in breast milk)
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
No significant food interactions reported. However, alcohol should be avoided due to additive CNS depression. Grapefruit juice may theoretically increase hydroxyzine levels via CYP3A4 inhibition, but clinical significance is minimal; caution is advised.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
First trimester: Considered safe; large studies show no increased risk of major malformations. Second trimester: No known specific risks. Third trimester: Use near term may cause neonatal withdrawal or CNS depression (drowsiness, irritability, tremors) due to placental transfer.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
Atarax (hydroxyzine) is excreted into breast milk in small amounts; M/P ratio approximately 0.7. Use with caution; monitor infant for sedation, irritability, or feeding difficulties. The American Academy of Pediatrics considers it compatible with breastfeeding, but alternative agents may be preferred.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
No dose adjustment is typically required for non-sedating use. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered clearance) may necessitate cautious titration; start at lowest effective dose and adjust based on clinical response. For severe pruritus in pregnancy, typical adult dosing (25 mg tid or qid) is used, but monitor for excessive sedation.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
ATARAX (hydroxyzine) is a first-generation antihistamine with anxiolytic and sedative properties. It is commonly used for pruritus, anxiety, and preoperative sedation. Note: QT prolongation risk at high doses; avoid in patients with known QT interval prolongation or concurrent use of other QT-prolonging agents. Onset of sedation is rapid, making it useful for sleep induction, but tolerance develops with chronic use. Anticholinergic effects (dry mouth, urinary retention) are dose-dependent.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Take exactly as prescribed; do not exceed recommended dose.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how this medication affects you.,Report any signs of allergic reaction (rash, difficulty breathing) or irregular heartbeat (palpitations, syncope) immediately.,Hydrate adequately to reduce dry mouth; sugar-free gum or candy can help.,Do not discontinue abruptly; follow your doctor's instructions for tapering if needed.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATARAX vs ADVIL ALLERGY SINUS, answered by our medical review team.
ATARAX is a Antihistamine that works by Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATARAX and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATARAX is: 25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATARAX and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATARAX is classified as Category C. First trimester: Considered safe; large studies show no increased risk of major malformations. Second trimester: No known specific risks. Third trimester: Use near term may cause n. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.